A Randomized, Open-Label, Multi-Center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-Line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney

Trial Profile

A Randomized, Open-Label, Multi-Center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-Line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Everolimus (Primary) ; Bevacizumab; Interferon alpha-2a
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms RECORD-2
  • Sponsors Novartis
  • Most Recent Events

    • 09 Aug 2017 This study has been discontinued in Belgium.
    • 01 May 2016 This trial was prematurely terminated in Czech Republic,Netherlands and in Hungary, Estonia, Italy (end date:2013-04-15) according to the European Clinical Trials Database.
    • 31 May 2013 Two-year overall survival and tolerability results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top